CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 31 enrolled
Drug / intervention
Aliskiren 150 mg +3 moredrug
Likely dose
Aliskiren 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03115853
NCT03115853Phase 4Completed
CompareCT.gov

The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function

Vanderbilt University Medical Center·interventional·Posted Apr 14, 2017·Updated Aug 25, 2017

In Brief

A Phase 4 clinical trial evaluating Aliskiren 150 mg, Placebo, and 2 other interventions for High Blood Pressure. Completed, enrolled 31 participants across 1 site.

Detailed Summary

Aliskiren (also called TekturnaTM) is a new drug for high blood pressure. Aliskiren works by blocking the actions of a substance called renin. Renin is a natural substance in the body that raises blood pressure. Renin is believed to contribute to the production of blood clots by increasing the amount of a substance known as Plasminogen Activator Inhibitor or PAI-1. This study will measure how aliskiren changes the amount of PAI-1 in the blood depending on the time of dosing. The purpose of this study is to find out if it is better to take aliskiren in the morning or at night.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHigh Blood Pressure
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 14, 2017
Enrollment StartJun 1, 2009
Primary CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 9.2 years ago

Interventions

Aliskiren 150 mgdrug

Aliskiren 150 mg daily for 2 weeks

Placebodrug

Placebo tablet for Aliskerin

HCTZdrug

HCTZ 25mg every day for 18 weeks

Aliskiren 300 mgdrug

Aliskiren 300 mg for 4 weeks